October 1, 2008 -- Genesis Pharmaceuticals Enterprises released its 2008 full-year (ended June 30) financial report, showing that the company continues to do well. In 2008, revenues for the company climbed 31% to $99.5 million, though net income was up a miniscule 2% at $22.5 million. The net income works out to $1.84 per share, fully diluted. The culprit for the relative shortfall in profit seems to have been Selling, General & Administrative costs, which rose 63% or $16 million in the year to $41.6 million. More details...Stock Symbol: (OTCBB: GNPH).
